Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

80.98USD
4:00pm EDT
Change (% chg)

$1.48 (+1.86%)
Prev Close
$79.50
Open
$79.44
Day's High
$81.15
Day's Low
$79.44
Volume
3,809,587
Avg. Vol
3,414,247
52-wk High
$83.81
52-wk Low
$58.03

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.60
Market Cap(Mil.): $204,684.20
Shares Outstanding(Mil.): 2,574.65
Dividend: 0.55
Yield (%): 2.77

Financials

  MRK.N Industry Sector
P/E (TTM): 25.04 30.96 35.38
EPS (TTM): 3.17 -- --
ROI: 12.55 12.01 11.72
ROE: 27.44 13.30 16.38

Deals of the day-Mergers and acquisitions

May 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

May 21 2019

Merck buys Peloton to expand its kidney cancer treatment portfolio

U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.

May 21 2019

REFILE-UPDATE 2-Merck buys Peloton to expand its kidney cancer treatment portfolio

May 21 U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.

May 21 2019

Merck to buy cancer drug developer Peloton for $1.05 bln in cash

May 21 Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.

May 21 2019

Merck's Keytruda fails as monotherapy in breast cancer study

Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

May 20 2019

UPDATE 1-Merck's Keytruda fails as monotherapy in breast cancer study

May 20 Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer.

May 20 2019

Merck's Keytruda fails as monotherapy in breast cancer study

May 20 Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the treatment as a monotherapy in patients with an aggressive type of breast cancer.

May 20 2019

Supreme Court gives Merck another shot to avoid Fosamax lawsuits

WASHINGTON The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation.

May 20 2019

UPDATE 3-U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits

* Lower courts to revisit case using Supreme Court guidance (Recasts first paragraph, adds comment from Merck and plaintiffs, details from ruling)

May 20 2019

CPPIB buys partial Keytruda royalty interest from British charity LifeArc

May 20 Canada Pension Plan Investment Board said it had paid about $1.3 billion for a part of British charity LifeArc's royalty interest from the sale of Merck & Co Inc's blockbuster cancer immunotherapy, Keytruda.

May 20 2019

Earnings vs. Estimates